Humana Inc. (NYSE:HUM) Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ trimmed its stake in shares of Humana Inc. (NYSE:HUM) by 0.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 24,171 shares of the insurance provider’s stock after selling 113 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Humana were worth $9,031,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. raised its position in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the period. Hantz Financial Services Inc. bought a new position in Humana in the 2nd quarter worth approximately $35,000. Family Firm Inc. bought a new position in Humana in the 2nd quarter worth approximately $37,000. Hollencrest Capital Management bought a new position in Humana in the 2nd quarter worth approximately $40,000. Finally, Riverview Trust Co bought a new position in Humana in the 2nd quarter worth approximately $44,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HUM has been the subject of a number of research reports. Royal Bank of Canada increased their price target on Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, September 5th. Baird R W raised Humana to a “hold” rating in a research note on Thursday, May 30th. TD Cowen increased their price target on Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Robert W. Baird started coverage on Humana in a research note on Thursday, May 30th. They set a “neutral” rating and a $374.00 price objective for the company. Finally, Oppenheimer raised their price objective on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Thirteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $398.70.

Humana Price Performance

Shares of NYSE:HUM opened at $310.41 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The business has a fifty day simple moving average of $357.71 and a 200 day simple moving average of $345.61. The firm has a market cap of $37.40 billion, a price-to-earnings ratio of 19.33, a P/E/G ratio of 2.56 and a beta of 0.50.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the business posted $8.94 earnings per share. As a group, sell-side analysts predict that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.14%. The ex-dividend date is Monday, September 30th. Humana’s payout ratio is 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.